OBJECTIVE: To evaluate the efficacy and toxicity of carboplatin, granulocyte-macrophage colony-stimulating factor (GM-CSF) and recombinant interferon gamma 1b (rIFN-gamma1b) in women with recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. METHODS: In this phase II study, patients with recurrent, platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer were treated with subcutaneous GM-CSF and rIFN-gamma1b before and after intravenous carboplatin until disease progression or unacceptable toxicity. All patients had measurable disease and a chemotherapy-free interval >6 months. Response was determined using RECIST criteria and CA 125 levels. RESULTS: Between 2003 and 2007, 59 patients received a median of 6 cycles of therapy (range, 1 to 13 cycles). Median age at enrollment was 61 years (range, 35 to 79 years). Median time to progression prior to enrollment was 11 months (range, 6 to 58 months). Of 54 patients evaluable for response, 9 (17%) had a complete response, 21 (39%) had a partial response, and 24 (44%) had progressive disease. The overall response rate was 56% (95% CI: 41% to 69%). With a median follow-up of 6.4 months, median time to progression was 6 months. Myeloid derived cells and platelets increased on day 9 of each chemotherapy cycle. The most common adverse effects were bone marrow suppression, carboplatin hypersensitivity, and fatigue. Responders reported improved quality of life. CONCLUSION: This pre and post-carboplatin cytokine regimen resulted in a reasonable response and a hematologic profile that could invite further evaluation of its components in the treatment of patients with ovarian cancer.
OBJECTIVE: To evaluate the efficacy and toxicity of carboplatin, granulocyte-macrophage colony-stimulating factor (GM-CSF) and recombinant interferon gamma 1b (rIFN-gamma1b) in women with recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. METHODS: In this phase II study, patients with recurrent, platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer were treated with subcutaneous GM-CSF and rIFN-gamma1b before and after intravenous carboplatin until disease progression or unacceptable toxicity. All patients had measurable disease and a chemotherapy-free interval >6 months. Response was determined using RECIST criteria and CA 125 levels. RESULTS: Between 2003 and 2007, 59 patients received a median of 6 cycles of therapy (range, 1 to 13 cycles). Median age at enrollment was 61 years (range, 35 to 79 years). Median time to progression prior to enrollment was 11 months (range, 6 to 58 months). Of 54 patients evaluable for response, 9 (17%) had a complete response, 21 (39%) had a partial response, and 24 (44%) had progressive disease. The overall response rate was 56% (95% CI: 41% to 69%). With a median follow-up of 6.4 months, median time to progression was 6 months. Myeloid derived cells and platelets increased on day 9 of each chemotherapy cycle. The most common adverse effects were bone marrow suppression, carboplatinhypersensitivity, and fatigue. Responders reported improved quality of life. CONCLUSION: This pre and post-carboplatin cytokine regimen resulted in a reasonable response and a hematologic profile that could invite further evaluation of its components in the treatment of patients with ovarian cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: A J González-Martín; E Calvo; I Bover; M J Rubio; A Arcusa; A Casado; B Ojeda; C Balañá; E Martínez; A Herrero; B Pardo; E Adrover; J Rifá; M J Godes; A Moyano; A Cervantes Journal: Ann Oncol Date: 2005-04-07 Impact factor: 32.976
Authors: K H Grabstein; D L Urdal; R J Tushinski; D Y Mochizuki; V L Price; M A Cantrell; S Gillis; P J Conlon Journal: Science Date: 1986-04-25 Impact factor: 47.728
Authors: C Marth; G H Windbichler; H Hausmaninger; E Petru; K Estermann; A Pelzer; E Mueller-Holzner Journal: Int J Gynecol Cancer Date: 2006 Jul-Aug Impact factor: 3.437
Authors: S Vadhan-Raj; H E Broxmeyer; W N Hittelman; N E Papadopoulos; S P Chawla; C Fenoglio; S Cooper; E S Buescher; R W Frenck; A Holian Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: P Allavena; F Peccatori; D Maggioni; A Erroi; M Sironi; N Colombo; A Lissoni; A Galazka; W Meiers; C Mangioni Journal: Cancer Res Date: 1990-11-15 Impact factor: 12.701
Authors: David Cella; Martin J Zagari; Christina Vandoros; Dennis D Gagnon; Hans-Jürgen Hurtz; Johan W R Nortier Journal: J Clin Oncol Date: 2003-01-15 Impact factor: 44.544
Authors: Sachin M Apte; Saroj Vadhan-Raj; Lorenzo Cohen; Roland L Bassett; Ilyssa O Gordon; Charles F Levenback; Pedro T Ramirez; Stacie T Gallardo; Rebecca S Patenia; Michael E Garcia; Revathy B Iyer; Ralph S Freedman Journal: J Transl Med Date: 2006-04-07 Impact factor: 5.531
Authors: Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos Journal: Gynecol Oncol Date: 2009-12-02 Impact factor: 5.482
Authors: Kristine A Donovan; Heidi S Donovan; David Cella; Martha E Gaines; Richard T Penson; Steven C Plaxe; Vivian E von Gruenigen; Deborah Watkins Bruner; Bryce B Reeve; Lari Wenzel Journal: J Natl Cancer Inst Date: 2014-07-08 Impact factor: 13.506